ClinicalTrials.gg
CompletedNCT04863664Updated Nov 4, 2026Results posted

Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)

An interventional study of Defibrillation (RV Implant) and Defibrillation (LBBAP Implant) in Ventricular Tachyarrhythmia, sponsored by Medtronic Cardiac Rhythm and Heart Failure. Completed at 55 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Medtronic Cardiac Rhythm and Heart Failure (part of Medtronic) · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,007
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Tachycardia, Ventricular by Medtronic — 2 open to participants now, 4 under way, none of them phase 3. Tachycardia, Ventricular · Medtronic.

Enrollment
Largest of 10
1,007 · median 307
Started
2021
the only one that year
No phase
7 of 19
2 open now
Registered
16th of 19
by date

Among the 19 studies in Tachycardia, Ventricular by Medtronic, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is one of 7 with no phase, and was the 16th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

2 of the 19 studies in Tachycardia, Ventricular by Medtronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Tachycardia, Ventricular by Medtronic, or all of them as a file.
02

Study summary

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.

The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.

Read the detailed description

The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (332 subjects enrolled).

03

Conditions studied

  • Ventricular Tachyarrhythmia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

LEADR Inclusion Criteria:

  • Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:

    • de novo Medtronic CRT-D system implant
    • de novo Medtronic ICD system implant (single or dual chamber)
  • Subject has, per local law and requirements, the minimum age for autonomously signing an ICF (minimum age of 18 years)
  • Subject is willing to undergo implant defibrillation testing if requested.
  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.

LEADR Exclusion Criteria:

  • Subject is unwilling or unable to personally provide .
  • Subject has for standard RV transvenous lead placement (e.g., mechanical right heart valve).
  • Subject is contraindicated for ≤1 mg dexamethasone acetate.
  • Subject has a of less than 12 months
  • For subject undergoing defibrillation testing the following medical conditions exclude them:

    • Pre-existing or suspected pneumothorax during implant
    • Current intracardiac left atrial or left ventricular (LV) thrombus
    • Severe aortic stenosis
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Unstable angina
    • less than 25%
    • Recent stroke or (within the last 6 months)
    • Known inadequate external defibrillation
    • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
  • Subject with any exclusion criteria as required by local law (e.g., age or other).
  • Pregnant women or breastfeeding women, or women of and who are not on a reliable form of birth regulation method or abstinence
  • Subject with an existing pacemaker (including transcatheter pacing system), ICD, or CRT device or leads
  • Subject with any evidence of active infection or undergoing treatment for an infection
  • Recent (or planned) cardiac surgery or stenting less than 1 month before implant
  • End stage renal disease
  • Subjects with IV classification
  • Subjects with a transplanted heart
  • Subjects with previously extracted leads
  • Subjects with Left Ventricular Assist Device

LEADR LBBAP Inclusion Criteria:

  • Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:

    a) De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)

  • Subject is 12 years of age or older and also is greater than 30 kg in weight at time of enrollment, has cardiac anatomy conducive to RV coil placement, and is allowed to participate in study per local law and requirements. Subjects from 12 years of age until adult also have a separate indication for pacing or CRT or are anticipated to develop one.
  • Subject provides written authorization and/or consent per institution and geographical requirements.
  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up
  • Subject is willing to undergo implant defibrillation testing if requested

LEADR LBBAP Exclusion Criteria:

  • Subject has contraindication for screw-in active fixation transvenous lead placement (e.g., mechanical right heart valve)
  • Subject is contraindicated for ≤1 mg dexamethasone acetate
  • Subject has a life expectancy of less than 12 months
  • For subject undergoing defibrillation testing the following medical conditions exclude them:

    • Pre-existing or suspected pneumothorax
    • Current intracardiac left atrial or LV thrombus
    • Severe aortic stenosis
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Unstable angina
    • Recent stroke or transient ischemic attack (within the last 6 months)
    • Known inadequate external defibrillation
    • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
  • Subject is pregnant or breastfeeding, or subject is of childbearing potential and not on a reliable form of birth regulation method or abstinence
  • Subject with an existing pacemaker (including transvenous and transcatheter pacing system), ICD (transvenous) or CRT-D (transvenous) device or leads
  • Subject with previous subcutaneous ICD (S-ICD), extravascular ICD (EV ICD) or Implantable Cardiac Monitor explanted within 30 days before implant
  • Subject with any evidence of active bacterial infection or undergoing treatment for a bacterial infection within the last 30 days
  • Recent (or planned) cardiovascular intervention within 30 days before or after implant, such as cardiac surgery, cardiac ablation, Percutaneous Coronary Intervention (PCI), or temporary cardiac pacing for >12 hours
  • Subjects with end stage renal disease
  • Subjects with NYHA IV classification
  • Subjects with a transplanted heart or on the waiting list for a heart transplant
  • Subjects with previously extracted leads
  • Subjects with Left Ventricular Assist Device
  • Subjects that are vulnerable adults
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,007 participants (actual)

Study arms

  • Experimental
    Intervention/Treatment (LEADR)

    Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing

    Device: Defibrillation (RV Implant)

  • Experimental
    Intervention/Treatment (LEADR LBBAP)

    Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing

    Device: Defibrillation (LBBAP Implant)

Interventions

  • DeviceDefibrillation (RV Implant)

    Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

  • DeviceDefibrillation (LBBAP Implant)

    Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

06

What researchers measure

Primary outcomes

  1. LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months

    Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.

    Time frame: Implant to 6 Months

  2. LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead

    Defibrillation testing will be completed in a subset of subjects at implant.

    Time frame: Day 1

  3. LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead

    Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.

    Time frame: Day 1

  4. LEADR LBBAP: The Lead-related Major Complication Rate at 3-months

    Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.

    Time frame: Implant to 3 Months

Secondary outcomes

  1. LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead

    Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.

    Time frame: up to 18 months

07

Results

Posted Nov 4, 2026

Participant flow

For LEADR, the first clinical study subject was enrolled on 21-Jun-2021. Enrollments and implants were considered to be completed on 01-Nov-2022. The first two LEADR LBBAP clinical study subjects were enrolled on 19-Apr-2024, with enrollments and implants being complete on 27-May-2025.

Participant flow — Overall Study
MilestoneIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
Started675332
Completed513277
Not completed16255

Outcome measures

PrimaryLEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months

Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.

Time frame:
Implant to 6 Months
Reported as:
Count of participants · Participants
LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months
ParticipantsIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months638—
Statistical analysis
  • Intervention/Treatment (LEADR) · Bayesian analysis methods · Major leadrelated complication free rate: 96.795% Credible Interval was 95.2% - 98%.
PrimaryLEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead

Defibrillation testing will be completed in a subset of subjects at implant.

Time frame:
Day 1
Reported as:
Number · % subjects succesfully defibrillated
LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
% subjects succesfully defibrillatedIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead95.8—
Statistical analysis
  • Intervention/Treatment (LEADR) · Bayesian analysis methods · Defibrillation success: 95.895% Credible Interval was 91% - 98.8%.
PrimaryLEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead

Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.

Time frame:
Day 1
Reported as:
Number · % subjects succesfully defibrillated
LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
% subjects succesfully defibrillatedIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead—100
Statistical analysis
  • Intervention/Treatment (LEADR LBBAP) · 2-sided exact binomial CI · Defibrillation success: 100 · 95% CI 97.7 to 100
PrimaryLEADR LBBAP: The Lead-related Major Complication Rate at 3-months

Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.

Time frame:
Implant to 3 Months
Reported as:
Count of participants · Participants
LEADR LBBAP: The Lead-related Major Complication Rate at 3-months
ParticipantsIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
LEADR LBBAP: The Lead-related Major Complication Rate at 3-months—310
Statistical analysis
  • Intervention/Treatment (LEADR LBBAP) · Kaplan-Meier · Lead-related complication free rate: 98 · 95% CI 96.5 to 99.6
SecondaryLEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead

Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.

Time frame:
up to 18 months
Reported as:
Count of participants · Participants
LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead
ParticipantsIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead656—
Statistical analysis
  • Intervention/Treatment (LEADR) · Bayesian analysis methods · Lead facture-free survival rate: 99.9395% Credible Interval was 99.75 - 100%.
  • Intervention/Treatment (LEADR) · Bayesian analysis methods · Lead facture-free survival rate: 99.9295% Credible Interval was 99.73% - 100%.

Adverse events

Collected over From enrollment until end of follow-up. For LEADR the average (SD) follow up was 31.7 (10.1) months. For LEADR LBBAP the average (SD) follow up was 9.9 (4) months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention/Treatment (LEADR)63/675 (9.3%)394/675 (58.4%)412/675 (61%)
Intervention/Treatment (LEADR LBBAP)8/332 (2.4%)119/332 (35.8%)143/332 (43.1%)
Most frequent serious events
Showing 10 of 464
Most frequent serious events
EventIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
Ventricular tachycardiaCardiac disorders59/67512/332
Atrial fibrillationCardiac disorders54/67515/332
Cardiac failureCardiac disorders46/67516/332
Cardiac failure congestiveCardiac disorders23/6753/332
PneumoniaInfections and infestations23/6755/332
Atrioventricular block completeCardiac disorders2/67511/332
Device inappropriate shock deliveryProduct issues22/6755/332
Lead dislodgementProduct issues21/6756/332
Acute kidney injuryRenal and urinary disorders20/6757/332
HypotensionVascular disorders19/6753/332
Most frequent other events
Showing 10 of 524
Most frequent other events
EventIntervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)
Ventricular tachycardiaCardiac disorders127/67522/332
Atrial fibrillationCardiac disorders50/67510/332
COVID-19Infections and infestations47/6754/332
DizzinessNervous system disorders26/6755/332
FatigueGeneral disorders and administration site conditions24/6756/332
Cardiac failureCardiac disorders21/6754/332
Device pacing issueProduct issues21/6753/332
Device stimulation issueProduct issues4/67510/332
DyspnoeaRespiratory, thoracic and mediastinal disorders19/6754/332
Cardiac perforationCardiac disorders0/6759/332

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
Mean61.9 ± 1364.9 ± 12.262.8 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
Female17496270
Male489231720
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
American Indian or Alaska Native112
Asian39241
Native Hawaiian or Other Pacific Islander202
Black or African American542175
White241144385
More than one race202
Unknown or Not Reported336164500
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
Hispanic or Latino23326
Not Hispanic or Latino234149383
Unknown or Not Reported418180598
Region of Enrollment
Region of Enrollment(Participants)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
Singapore606
Hong Kong321143
United States270154424
Japan331750
United Kingdom10414
Malaysia453075
Portugal10010
Spain18523
Canada682492
Austria10010
Netherlands066
Belgium088
China221739
Denmark606
Poland099
Italy22022
Australia583593
France201232
Serbia22022
Germany23023
Height
Height(centimeters)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
Mean171.3 ± 10.5171.1 ± 10.4171.2 ± 10.5
Weight
Weight(kilograms)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
Mean84.1 ± 22.383.7 ± 21.484.0 ± 22.0
BMI
BMI(kg/m^2)Intervention/Treatment (LEADR)Intervention/Treatment (LEADR LBBAP)Total
Mean28.5 ± 6.328.4 ± 6.128.5 ± 6.3
08

Study locations

55 sites
  • LEADR: Heart Center Research
    Huntsville, Alabama 35801, United States
  • LEADR LBBAP: Torrance Memorial Medical Center
    Torrance, California 90505, United States
  • LEADR: Hartford Hospital
    Hartford, Connecticut 06106, United States
  • LEADR: University of South Florida
    Tampa, Florida 33606, United States
  • LEADR & LEADR LBBAP: Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
  • LEADR: Saint Luke's Mid America Heart Institute
    Kansas City, Missouri 64111, United States
  • LEADR: Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • LEADR: Lourdes Cardiology Services
    Voorhees Township, New Jersey 08034, United States
  • LEADR: Presbyterian Heart Group
    Albuquerque, New Mexico 87108, United States
  • LEADR & LEADR LBBAP: South Shore University Hospital/Northwell Health
    Bay Shore, New York 11030, United States
  • LEADR: TriHealth Hatton Research Institute
    Cincinnati, Ohio 45202, United States
  • LEADR LBBAP: The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • LEADR: Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • LEADR LBBAP: The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • LEADR: Lehigh Valley Hospital - Cedar Crest
    Allentown, Pennsylvania 18103, United States
  • LEADR: Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • LEADR LBBAP: Geisinger Wyoming Valley Medical Center
    Wilkes-Barre, Pennsylvania 18711, United States
  • LEADR& LEADR LBBAP: Vanderbilt University medical Center
    Nashville, Tennessee 37232, United States
  • LEADR: Texas Cardiac Arrhythmia Research Foundation
    Austin, Texas 78705, United States
  • LEADR: Texas Health Fort Worth Hospital
    Fort Worth, Texas 76104, United States
  • LEADR & LEADR LBBAP: University of Virginia Medical Center
    Charlottesville, Virginia 22903, United States
  • LEADR & LEADR LBBAP: Virginia Commonwealth University Health System
    Richmond, Virginia 23298, United States
  • LEADR LBBAP: Aurora St. Luke's Hospital
    Milwaukee, Wisconsin 53215, United States
  • LEADR & LEADR LBBAP: The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • LEADR: Ashford Hospital
    Ashford, South Australia 8032, Australia
  • LEADR & LEADR LBBAP: Royal Adelaide
    Norwood, South Australia 5000, Australia
  • LEADR &LEADR LBBAP: Canberra Hospital
    Garran, 2605, Australia
  • LEADR: Universitätsklinikum Krems
    Krems, Mitterweg 3500, Austria
  • LEADR LBBAP: Universitair Ziekenhuis Antwerpen
    Edegem, Antwerp 2650, Belgium
  • LEADR: University of Calgary
    Calgary, Alberta T2N 4N1, Canada
  • LEADR: Southlake Regional Health Centre
    Newmarket, Ontario L3Y8C3, Canada
  • LEADR & LEADR LBBAP: Institut Universitaire de Cardiologie et de Pneumologie de Quebec
    Québec, Quebec G1V 4G5, Canada
  • LEADR: Shanxi Cardiovascular Hospital
    Taiyuan, Shanxi 030000, China
  • LEADR & LEADR LBBAP: West China Hospital of Sichuan University
    Chengdu, China
  • LEADR: Rigshospitalet
    Copenhagen, 2100, Denmark
  • LEADR: Centre Hospitalier Universitaire de Grenoble - Site Nord
    La Tronche, 38700, France
  • LEADR LBBAP: OC Santé - Clinique du Millénaire
    Montpellier, 34960, France
  • LEADR: CHU Hôpitaux de Rouen - Hôpital Charles Nicolle
    Rouen, 76031, France
  • LEADR: Klinikum Bielefeld Kardiologie
    Bielefeld, Bielefeld 33604, Germany
  • LEADR & LEADR LBBAP: Queen Mary Hospital
    Hong Kong, Hong Kong
  • LEADR: Princess Margaret Hospital
    Lai Chi Kok, 999077, Hong Kong
  • LEADR: Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • LEADR & LEADR LBBAP: Kokura Memorial Hospital
    Kitakyushu, Fukuoka 802-8555, Japan
  • LEADR & LEADR LBBAP: National Cerebral and Cardiovascular Center
    Suita, Osaka 564-8565, Japan
  • LEADR: Tokyo Women's Medical University Hospital
    Shinjuku-Ku, Tokyo 162-8666, Japan
  • LEADR & LEADR LBBAP: Institut Jantung Negara - National Heart Institute
    Kuala Lumpur, 50400, Malaysia
  • LEADR LBBAP: Maastricht Universitair Medisch Centrum
    Maastricht, Limburg, Netherlands
  • LEADR LBBAP: Szpital Uniwersytecki w Krakowie
    Krakow, Poland
  • LEADR: Centro Hospitalar de Lisboa Ocidental, E.P.E. Hospital de Santa Cruz Cardiology
    Carnaxide, 2790-134, Portugal
  • LEADR: Klinicki Centar Srbije Pejsmejker centar
    Belgrade, Serbia
  • LEADR: Ng Teng Fong General Hospital
    Singapore, Singapore, Singapore
  • LEADR LBBAP: Hospital Universitario Virgen de las Nieves
    Granada, Granada 18014, Spain
  • LEADR: Hospital Universitari Bellvitge
    L'Hospitalet de Llobregat, Spain
  • LEADR: Hospital Universitario y Politécnico La Fe
    Valencia, 46026, Spain
  • LEADR & LEADR LBBAP: Imperial College Healthcare NHS Trust - Hammersmith Hospital
    London, W12 0HS, United Kingdom
09

References and documents

Publications

  • Crossley GH 3rd, Mason PK, Hansky B, De Filippo P, Shah MJ, Philippon F, Sholevar D, Richardson TD, West MB, Dinerman J, Dawson J, Himes A, Severseike L, Thompson AE, Sanders P. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025 Feb;22(2):302-310. doi: 10.1016/j.hrthm.2024.09.005. Epub 2024 Sep 26. PubMed 39341436 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2025, 50 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's 50 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 28, 2021
StartActual
Jun 21, 2021
Primary completionActual
Sep 3, 2025
CompletionActual
Nov 6, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Enrollment
998→1007
Nov 4, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedLEADR: Estimate the rateRate of majorMajor Lead complicationComplication-free rateRate at 6 monthsMonthsTime frame: Implant to 6 Months
  • EditedLEADR: Percentage of subjects successfully defibrillatedSubjects Successfully Defibrillated at implant withImplant With the Next Generation ICD leadLeadTime frame: Day 1
  • EditedLEADR LBBAP: Percentage of subjects successfully defibrillatedSubjects Successfully Defibrillated at implant withImplant With the Next Generation ICD leadLeadTime frame: Day 1
  • EditedLEADR LBBAP: The leadLead-related major complication rateMajor Complication Rate at 3-monthsTime frame: Implant to 3 Months
Nov 4, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedLEADR: Estimate the fractureFracture-free rateRate of the Next Generation ICD leadLeadTime frame: up to 24 months → up to 18 months
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Enrollment 998→1007
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedLEADR: Estimate the rateRate of majorMajor Lead complicationComplication-free rateRate at 6 monthsMonthsTime frame: Implant to 6 Months
    • EditedLEADR: Percentage of subjects successfully defibrillatedSubjects Successfully Defibrillated at implant withImplant With the Next Generation ICD leadLeadTime frame: Day 1
    • EditedLEADR LBBAP: Percentage of subjects successfully defibrillatedSubjects Successfully Defibrillated at implant withImplant With the Next Generation ICD leadLeadTime frame: Day 1
    • EditedLEADR LBBAP: The leadLead-related major complication rateMajor Complication Rate at 3-monthsTime frame: Implant to 3 Months
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedLEADR: Estimate the fractureFracture-free rateRate of the Next Generation ICD leadLeadTime frame: up to 24 months → up to 18 months
    + 3 other changes: description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04863664
Responsible party
Sponsor
First posted
Apr 28, 2021
Start date
Jun 21, 2021
Primary completion
Sep 3, 2025
Completion
Nov 6, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

George Crossley, MD
principal investigator · Vanderbilt University (LEADR)
Pugazhendhi Vijayaraman, MD
principal investigator · Geisinger Medical Center (LEADR LBBAP)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion